MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $10.90 (270.75% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Jefferies GroupUpgradeHold -> Buy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$16.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Piper JaffrayDowngradeOverweight -> Neutral$15.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016JMP SecuritiesLower Price Target$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Bank of AmericaDowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.21)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.17)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.20)($0.23)
Q2 20165($0.25)($0.17)($0.22)
Q3 20165($0.26)($0.16)($0.22)
Q4 20165($0.26)$0.12($0.16)
(Data provided by Zacks Investment Research)
Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline
06/24/16 02:47 PMShare Volatility Check for: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Press Telegraph
06/21/16 07:33 AMStrong Buy Calls Count For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) At 3 - Investor Newswire
06/21/16 07:33 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Current Analyst Ratings - Fiscal Standard
06/19/16 02:42 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rating Update - Investor Newswire
06/19/16 07:29 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 10:41 AMTrading updates about two Stocks: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) , BioCryst Pharmaceuticals ... - Street Updates
06/13/16 03:01 PMAnalyst Overview: FirstMerit Corporation (NASDAQ:FMER), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Beacon Chronicle
06/13/16 10:49 AMHC Stocks to watch for: Biostar Pharmaceuticals Inc (NASDAQ:BSPM), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - share market updates (press release)
06/11/16 02:50 PMBioCryst Pharmaceuticals Inc. (BCRX) Drops 12.89% on June 09 - Equities.com
06/10/16 02:48 PMOverview of Price Moves: Zoetis Inc. (NYSE:ZTS) , BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Street Updates
06/09/16 11:41 AMBioCryst Pharmaceuticals Inc. (BCRX) is Trading Higher on Unusual Volume for June 07 - Equities.com
06/07/16 11:00 AMBiocryst Pharmaceuticals (BCRX) Is Today's Strong On High Volume Stock - TheStreet.com
06/06/16 08:12 PMBIOCRYST PHARMACEUTICALS INC. (NASDAQ:BCRX) Financial Condition Compared to S&P 500 - CML News
06/06/16 10:27 AMRecent Update on Price Fluctuations: Wright Medical Group N.V. (WMGI) , BioCryst Pharmaceuticals, Inc. (BCRX) - Street Updates
06/05/16 10:37 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Broker Price Targets For The Coming Week - Share Trading News
06/04/16 11:16 AMAnalytical Report of the Stocks: Euronav NV (NYSE:EURN), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Beacon Chronicle
06/03/16 11:18 AMBioCryst Pharmaceuticals, Inc. (BCRX) Upgraded to Buy by Jefferies Group - Let Me Know About This
06/02/16 11:32 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, ...and more »
06/02/16 11:32 AMStocks Recent Trading Summary: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Portola Pharmaceuticals, Inc ... - Street Updates - Stocks Recent Trading Summary: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Portola Pharmaceuticals, Inc ...Street UpdatesOn 6/1/2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) highlighted upward shift of +1.77% or +0.06 points to $3.45. The company traded a volume of 1.03 million shares under average volume of 1.2 million shares. Trailing twelve month period, the firm ...and more »
06/01/16 11:16 AMStock Review and Earnings Check on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - HNN - Stock Review and Earnings Check on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report quarterly EPS of $-0.24. The company's next earnings report is expected to be ...and more »
05/31/16 02:50 PMHC Stocks Growth: TG Therapeutics Inc (NASDAQ:TGTX), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - share market updates (press release) - HC Stocks Growth: TG Therapeutics Inc (NASDAQ:TGTX), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)share market updates (press release)Shares of TG Therapeutics Inc (NASDAQ:TGTX) ended Friday session in green amid volatile trading. The shares closed up +0.51 points or 7.06% at $7.73 with 843,587.00 shares getting traded. Post opening the session at $7.85, the shares hit an intraday ...and more »
05/30/16 08:19 AMAfter Last Week What Do Analysts Think Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Share Trading News - After Last Week What Do Analysts Think Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Share Trading News05/30/2014 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at ING. They now have a USD 24 price target on the stock. The share price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was up +0.60% during the last trading ...and more »
05/28/16 05:02 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) One-Year Price Target At $6.75 - Investor Newswire - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) One-Year Price Target At $6.75Investor NewswireFirst Call has set a 52-week price target of $6.75 on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-0.25 and for underway fiscal at $-1.06. This estimate for ...and more »
05/26/16 06:19 PMETF’s with exposure to BioCryst Pharmaceuticals, Inc. : May 26, 2016 -
05/26/16 08:20 AMInsiders Are Gradually Buying BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Wall Street Hints and News - Insiders Are Gradually Buying BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have increased their position in the stock by 172.15% over the past 6 months. Insiders now own 1.50% of total outstanding shares. There are both legal and ...and more »
05/25/16 10:09 PMThe Statistics Don't Lie: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Preview - iStreetWire - The Statistics Don't Lie: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings PreviewiStreetWireBioCryst Pharmaceuticals, Inc. (BCRX) added 4.04% to reach at the floor price of $3.35 as the company is set to share its next quarterly earnings on August 04, 2016. BCRX stock trades between $3.14 and $3.38 before the earnings release. Let's take a ...
05/25/16 10:09 PMMovers inside Traders Limelight: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Ultragenyx Pharmaceutical Inc ... - Street Updates - Movers inside Traders Limelight: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Ultragenyx Pharmaceutical Inc ...Street UpdatesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) accumulated +4.04%, closing at $3.35 after floating between $3.14 and $3.38. The company has market capitalization of $246.87M. It has twelve month low of $1.63 and twelve month high of $16.83.Statistics Don't Lie: BioCryst Pharmaceuticals (NASDAQ:BCRX) Earnings PreviewiStreetWireall 2 news articles »
05/25/16 10:49 AMBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
05/23/16 09:57 AMStock Rating Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Wall Street Hints and News - Stock Rating Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 2.44 on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Covering ...and more »
05/23/16 09:57 AMNotable Moving Stocks:Humana Inc. (NYSE:HUM) , BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Street Updates - Notable Moving Stocks:Humana Inc. (NYSE:HUM) , BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Street UpdatesOn 5/20/2016, Humana Inc. (NYSE:HUM) ended trading session higher at $169.60 with +0.75%. The company traded a volume of 1.41 million shares as comparison to average volume of 871.45 thousand shares. During the 52 –week period, the stock's price ...and more »
05/21/16 08:26 AMBioCryst Pharmaceuticals Inc. (BCRX) Jumps 6.07% on May 20 - Equities.com - BioCryst Pharmaceuticals Inc. (BCRX) Jumps 6.07% on May 20Equities.comBioCryst Pharmaceuticals Inc. (BCRX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 6.07% to $3.32, representing a gain of $0.19 per share. Some 989,683 shares traded hands on 6,377 trades, compared with an ...and more »
05/19/16 05:08 PMInsiders Are Buying BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Wall Street Hints and News - Insiders Are Buying BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have increased their position in the stock by 172.15%. Insiders now own 1.50% of total outstanding shares. There are both legal and illegal types of insider ...and more »
05/18/16 05:04 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Comprehensive Income At $-0.206 - RealistInvestor.com - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Comprehensive Income At $-0.206RealistInvestor.comFor the year ended 2015-12-31, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)comprehensive income was $-0.206 millions whereas for the quarter ended 2015-12-31, it was $-0.206 millions. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted ...Latest Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Share Trading NewsWatch List: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Alcobra Ltd. (NASDAQ:ADHD), Black Box Corporation ...KC RegisterBiocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Short Interest Increased By 9.16%The PostTrade Callsall 6 news articles »
05/18/16 09:12 AMLatest Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Share Trading News - Latest Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Share Trading News02/09/2016 – BioCryst Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 5 price target on the stock. 02/09/2016 – BioCryst Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR ...and more »
05/17/16 12:04 PMBIOCRYST PHARMACEUTICALS INC Financials -
05/17/16 08:50 AMAnalysts Expect IWO Will Reach $164 - TRVN), BioCryst Pharmaceuticals, Inc. (NASD: BCRX), and MacroGenics, Inc (NASD: MGNX). Although TRVN has traded at a recent price of $6.32/share, the average analyst target is 140.73% higher at $15.21/share. Similarly, BCRX has 133.40% upside from the ...
05/16/16 04:49 PMConsensus Rating Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Wall Street Hints and News - Consensus Rating Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 2.44 on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a ...and more »
05/16/16 10:00 AMTwo Buzzers within Investors Radar: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Accelerate Diagnostics, Inc ... - Street Updates - Two Buzzers within Investors Radar: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Accelerate Diagnostics, Inc ...Street UpdatesOn 5/13/2016, shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose +2.46% in trading session and finally closed at $2.91. The company most recent volume stood at 636.99 thousand shares as compared to its average volume of 1.37 million shares ...and more »
05/12/16 05:26 PMNoteworthy Price Swings: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Ovascience Inc. (NASDAQ:OVAS) - Street Updates - Noteworthy Price Swings: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , Ovascience Inc. (NASDAQ:OVAS)Street UpdatesOn 5/11/2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ended trading session lower at $2.83 with -4.39%. The company traded a volume of 573.7 thousand shares as comparison to average volume of 1.4 million shares. During the 52 –week period, ...EarningsExpectation Watch List: BioCryst Pharmaceuticals (BCRX)News Oracleall 2 news articles »
05/12/16 01:55 PMETF’s with exposure to BioCryst Pharmaceuticals, Inc. : May 12, 2016 -
05/11/16 10:21 AMBioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 03:35 AMBioCryst Pharmaceuticals Inc. (BCRX) Jumps 7.75% on May 09 - Equities.com - BioCryst Pharmaceuticals Inc. (BCRX) Jumps 7.75% on May 09Equities.comBioCryst Pharmaceuticals Inc. (BCRX) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 7.75% to $3.06, representing a gain of $0.22 per share. Some 736,680 shares traded hands on 3,762 trades, compared with ...and more »
05/09/16 10:25 PMCheck on Analyst Ratings BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - B.O.D.Y Confidential - Check on Analyst Ratings BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 2.44 on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to ...and more »
05/09/16 02:04 PMEdited Transcript of BCRX earnings conference call or presentation 5-May-16 3:00pm GMT -
05/09/16 01:06 PMBIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/06/16 05:21 PMEarnings Report: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - News Oracle - Earnings Report: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)News OracleLast Trade: The Company fell -9.00% and finished at $2.73. The daily volume was measured at 1.90 million shares. The 52-week high of the share price is $16.83 and the 52-week low is $1.63. The company has a market cap of $204.83 million. Its latest ...and more »
05/06/16 05:21 PMHC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following 1Q:16 Update - Smarter Analyst - Web Breaking NewsHC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following 1Q:16 UpdateSmarter AnalystBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress. The company reported revenues of $4.8 million, down from $6.8 million in 1Q15.BioCryst Pharmaceuticals Inc. (BCRX) Drops 7.41% on May 04Equities.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst ReviewRisers & FallersTrade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Weak On High Relative Volume StockTheStreet.comWeb Breaking News -Seneca Globe -The Postall 17 news articles »
05/06/16 03:57 AMBioCryst Pharmaceuticals Inc. (BCRX) Drops 7.41% on May 04 - Equities.com - BioCryst Pharmaceuticals Inc. (BCRX) Drops 7.41% on May 04Equities.comBioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 7.41% to $3.00, a loss of $-0.24 per share. Starting at an opening price of $3.20 a share, the stock traded between $2.97 and $3.29 ...and more »
05/05/16 10:50 PMPrice Fluctuations to Observe: Vascular Biogenics Ltd. (NASDAQ:VBLT) , BioCryst Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - Price Fluctuations to Observe: Vascular Biogenics Ltd. (NASDAQ:VBLT) , BioCryst Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) moved in red zone with decline of -0.24 points or -7.41% to $3.00. The company has a market worth of $220.01M.Total 1.01 million shares were exchanged in last trading session as opposed to average ...
05/05/16 05:40 PMBioCryst Pharmaceuticals Inc. (BCRX) Drops 9% on May 05 - Equities.com - BioCryst Pharmaceuticals Inc. (BCRX) Drops 9% on May 05Equities.comBioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Thursday May 05 as the stock slid 9% to $2.73, a loss of $-0.27 per share. Starting at an opening price of $2.67 a share, the stock traded between $2.49 and $2.98 ...and more »
About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company's Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BCRX
  • CUSIP: 09058V10
Key Metrics:
  • Previous Close: $2.94
  • 50 Day Moving Average: $3.155
  • 200 Day Moving Average: $4.642
  • P/E Ratio: N/A
  • P/E Growth: -0.130
  • Market Cap: $207.44M
  • Current Quarter EPS Consensus Estimate: $-1.060 EPS
Additional Links:
BioCryst Pharmaceuticals (NASDAQ:BCRX) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha